Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887323 · ClinicalTrials.gov registry record
LBBAP Data Collection Registry
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 221
- Enrollment target
NCT05887323: Completed study, sponsored by Abbott Medical Devices.
NCT05887323 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 221 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05887323 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 221 participants
- Enrollment target
Study Summary
The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.
Primary Outcome
The primary safety endpoint evaluates a LBBAP lead related SADE rate which is an appropriate measure for safety and consistent with the primary safety endpoints used for evaluating performance of the transvenous right ventricular lead.
Interventions
- DEVICE Implantation of the Tendril 2088 lead in the LBBA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-07-11 |
What the finished NCT05887323 record still lists
NCT05887323 is an observational study that tracks outcomes without assigning an intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Implantation of the Tendril 2088 lead in the LBBA is the first listed.
NCT05887323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05887323 about?
NCT05887323 is a clinical study titled "LBBAP Data Collection Registry". The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.
What is the current status of trial NCT05887323?
This trial is currently completed. The enrollment target is 221 participants. The study started on 2023-04-25. Estimated completion is 2023-07-11.
What interventions are being tested in trial NCT05887323?
The interventions under investigation include: Implantation of the Tendril 2088 lead in the LBBA (DEVICE).
Who is sponsoring clinical trial NCT05887323?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI